Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic Prostate Cancer: Meta-Analysis of Randomized Controlled Trials

Author(s): Muhammed Rashid, Madhan Ramesh*, K. Shamshavali, Amit Dang, Himanshu Patel, Krishna Undela.

Journal Name: Reviews on Recent Clinical Trials

Volume 15 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Prostate cancer (PCa) is the sixth primary cause of cancer death. However, conflicts are present about the efficacy and safety of Non-steroidal anti-androgens (NSAA) for its treatment. The aim of this study was to assess the efficacy and safety of NSAAs versus any comparator for the treatment of advanced or metastatic PCa (mPCa).

Methods: MEDLINE and the Cochrane Library were searched. References of included studies and clinicaltrials.gov were also searched for relevant studies. Only English language studies after 1990 were considered for review. Randomized controlled trials (RCTs) examining the efficacy and safety of NSAAs as compared with any other comparator including surgery or chemotherapy in mPCa patients were included. The outcomes include efficacy, safety and the tolerability of the treatment. The Cochrane Risk of Bias Assessment Tool was used for quality assessment. Two authors were independently involved in the selection, extraction and quality assessment of included studies and disagreements were resolved by discussion or by consulting a third reviewer.

Results: Fifty-eight out of 1307 non-duplicate RCTs with 29154 patients were considered for the review. NSAA showed significantly better progression-free survival [PFS] (Hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.46-0.78; P=0.0001), time to distant metastasis or death [TTD] (HR, 0.80; 95% CI 0.73-0.91; P<0.0001), objective response (Odds ratio [OR], 1.64; 95% CI 1.06-2.54; P=0.03) and clinical benefits (OR, 1.33; 95% CI 1.08-1.63; P=0.006) as compared to the control group. There was no significant difference observed between the groups in terms of overall survival (HR, 0.95; 95%CI, 0.87-1.03; P=0.18) and time to progression (HR, 0.93; 95% CI 0.77-1.11; P=0.43). Treatment-related adverse events were more with the NSAA group, but the discontinuation due to lack of efficacy reason was 43% significantly lesser than the control group in patients with mPCa. Rest of the outcomes were appeared to be non-significant.

Conclusion: Treatment with NSAA was appeared to be better efficacious with respect to PFS, TTD, and response rate with considerable adverse events when compared to the control group in patients with metastatic PCa.

Keywords: Meta-analysis, metastatic, nonsteroidal anti-androgens, prostate cancer, medline, Randomized Controlled Trials (RCTs).

[1]
Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene 2014; 2: 596-605.
[http://dx.doi.org/10.1016/j.mgene.2014.07.007] [PMID: 25606442]
[2]
Park JC, Eisenberger MA. Advances in the treatment of metastatic prostate cancer. Mayo Clin Proc 2015; 90(12): 1719-33.
[http://dx.doi.org/10.1016/j.mayocp.2015.10.010] [PMID: 26653301]
[3]
Kunath F, Grobe HR, Rücker G, et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev 2014; (6): CD009266
[http://dx.doi.org/10.1002/14651858.CD009266.pub2] [PMID: 24979481]
[4]
Akaza H, Hinotsu S, Usami M, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009; 115(15): 3437-45.
[http://dx.doi.org/10.1002/cncr.24395] [PMID: 19536889]
[5]
Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 2000; 132(7): 566-77.
[http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00009] [PMID: 10744594]
[6]
Group PC. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet 2000; 355(9214): 1491-8.
[http://dx.doi.org/10.1016/S0140-6736(00)02163-2] [PMID: 10801170]
[7]
Iversen P. Antiandrogen monotherapy: Indications and results. Urology 2002; 60(3)(Suppl. 1): 64-71.
[http://dx.doi.org/10.1016/S0090-4295(02)01576-5] [PMID: 12231053]
[8]
Botrel TE, Clark O, dos Reis RB, et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: A systematic review and meta-analysis. BMC Urol 2014; 14(1): 9.
[http://dx.doi.org/10.1186/1471-2490-14-9] [PMID: 24460605]
[9]
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371(5): 424-33.
[http://dx.doi.org/10.1056/NEJMoa1405095] [PMID: 24881730]
[10]
Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. Ann Oncol 2014; 25(2): 429-34.
[http://dx.doi.org/10.1093/annonc/mdt571] [PMID: 24478320]
[11]
Kim CS, Choi YD, Lee SE, et al. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer. Medicine (Baltimore) 2017; 96(27)e7223
[http://dx.doi.org/10.1097/MD.0000000000007223] [PMID: 28682871]
[12]
Bown MJ, Sutton AJ. Quality control in systematic reviews and meta-analyses. Eur J Vasc Endovasc Surg 2010; 40(5): 669-77.
[http://dx.doi.org/10.1016/j.ejvs.2010.07.011] [PMID: 20732826]
[13]
Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): Results from a randomised, phase 3 trial. Lancet Oncol 2015; 16(5): 509-21.
[http://dx.doi.org/10.1016/S1470-2045(15)70113-0] [PMID: 25888263]
[14]
Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): A randomised, double-blind, phase 2 study. Lancet Oncol 2016; 17(2): 153-63.
[http://dx.doi.org/10.1016/S1470-2045(15)00518-5] [PMID: 26774508]
[15]
Graff JN, Baciarello G, Armstrong AJ, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: Results from PREVAIL. Ann Oncol 2016; 27(2): 286-94.
[http://dx.doi.org/10.1093/annonc/mdv542] [PMID: 26578735]
[16]
Saad F, de Bono J, Shore N, et al. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Eur Urol 2015; 67(2): 223-30.
[http://dx.doi.org/10.1016/j.eururo.2014.08.025] [PMID: 25171902]
[17]
Sridhar SS, Joshua AM, Gregg R, et al. A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2015; 13(2): 124-9.
[http://dx.doi.org/10.1016/j.clgc.2014.06.001] [PMID: 24993934]
[18]
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367(13): 1187-97.
[http://dx.doi.org/10.1056/NEJMoa1207506] [PMID: 22894553]
[19]
Usami M, Akaza H, Arai Y, et al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis 2007; 10(2): 194-201.
[http://dx.doi.org/10.1038/sj.pcan.4500934] [PMID: 17199134]
[20]
Ansari MS, Gupta NP, Hemal AK, Dogra PN, Seth A. Combined androgen blockade in the management of advanced prostate cancer: A sensible or ostensible approach. Int J Urol 2004; 11(12): 1092-6.
[http://dx.doi.org/10.1111/j.1442-2042.2004.00953.x] [PMID: 15663681]
[21]
Schröder FH, Whelan P, de Reijke TM, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the “European Organization for Research and Treatment of Cancer” (EORTC) Protocol 30892. Eur Urol 2004; 45(4): 457-64.
[http://dx.doi.org/10.1016/j.eururo.2003.11.016] [PMID: 15041109]
[22]
Akaza H, Yamaguchi A, Matsuda T, et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004; 34(1): 20-8.
[http://dx.doi.org/10.1093/jjco/hyh001] [PMID: 15020659]
[23]
Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K. Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 2004; 11(2): 103-9.
[http://dx.doi.org/10.1111/j.1442-2042.2004.t01-1-00748.x] [PMID: 14706014]
[24]
Hedlund PO, Ala-Opas M, Brekkan E, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002; 36(6): 405-13.
[http://dx.doi.org/10.1080/003655902762467549] [PMID: 12623503]
[25]
Boccardo F, Barichello M, Battaglia M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: Updated results of a multicentric trial. Eur Urol 2002; 42(5): 481-90.
[http://dx.doi.org/10.1016/S0302-2838(02)00435-9] [PMID: 12429158]
[26]
Ozono S, Okajima E, Yamaguchi A, et al. A prospective randomized multicenter study of chlormadinone acetate versus flutamide in total androgen blockade for prostate cancer. Jpn J Clin Oncol 2000; 30(9): 389-96.
[http://dx.doi.org/10.1093/jjco/hyd106] [PMID: 11095136]
[27]
Tyrrell CJ, Altwein JE, Klippel F, et al. Comparison of an LH–RH analogue (Goeserelin Acetate,‘Zoladex’) with CAB in advanced prostate cancer: Final survival results of an international multicentre randomized–trial. Eur Urol 2000; 37(2): 205-11.
[http://dx.doi.org/10.1159/000020119] [PMID: 10705200]
[28]
Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: Effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 2000; 55(3): 328-33.
[http://dx.doi.org/10.1016/S0090-4295(99)00580-4] [PMID: 10699602]
[29]
Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian prostate cancer project study. J Clin Oncol 1999; 17(7): 2027-38.
[http://dx.doi.org/10.1200/JCO.1999.17.7.2027] [PMID: 10561254]
[30]
Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036-42.
[http://dx.doi.org/10.1056/NEJM199810083391504] [PMID: 9761805]
[31]
Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJ. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? Urology 2000; 55(3): 391-5.
[http://dx.doi.org/10.1016/S0090-4295(99)00574-9] [PMID: 10699617]
[32]
Bono AV, DiSilverio F, Robustelli della Cuna G, et al. Complete androgen blockade versus chemical castration in advanced prostatic cancer: Analysis of an Italian multicentre study. Urol Int 1998; 60(Suppl. 1): 18-24.
[http://dx.doi.org/10.1159/000056541] [PMID: 9563140]
[33]
Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: Final analysis of EORTC phase III trial 30853. Eur Urol 1998; 33(2): 144-51.
[http://dx.doi.org/10.1159/000019546] [PMID: 9519355]
[34]
Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51(3): 389-96.
[http://dx.doi.org/10.1016/S0090-4295(98)00004-1] [PMID: 9510340]
[35]
Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial. Urology 1997; 50(3): 330-6.
[http://dx.doi.org/10.1016/S0090-4295(97)00279-3] [PMID: 9301693]
[36]
Dijkman GA. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol 1997; 158: 160-3.
[37]
Zalcberg JR, Raghaven D, Marshall V, Thompson PJ. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial. Br J Urol 1996; 77(6): 865-9.
[http://dx.doi.org/10.1046/j.1464-410X.1996.01517.x] [PMID: 8705223]
[38]
Iversen P, Tveter K, Varenhorst E. Randomised study of Casodex 50 MG monotherapy vs. orchidectomy in the treatment of metastatic prostate cancer. Scand J Urol Nephrol 1996; 30(2): 93-8.
[http://dx.doi.org/10.3109/00365599609180896] [PMID: 8738052]
[39]
Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A. Combination treatment versus LHRH alone in advanced prostatic cancer. Urol Int 1996; 56(Suppl. 1): 13-7.
[http://dx.doi.org/10.1159/000282863] [PMID: 8776812]
[40]
Schellhammer P, Sharifi R, Block N, et al. Maximal androgen blockade for patients with metastatic prostate cancer: Outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology 1996; 47(1A)(Suppl.): 54-60.
[http://dx.doi.org/10.1016/S0090-4295(96)80010-0] [PMID: 8560679]
[41]
Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996; 47(1A)(Suppl.): 38-43.
[http://dx.doi.org/10.1016/S0090-4295(96)80007-0] [PMID: 8560677]
[42]
Chodak G, Sharifi R, Kasimis B, Block NL. MaCramalla E, Kennealey GT. Singleagent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995; 46(6): 849-55.
[http://dx.doi.org/10.1016/S0090-4295(99)80356-2] [PMID: 7502428]
[43]
Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 1995; 45(5): 745-52.
[http://dx.doi.org/10.1016/S0090-4295(99)80077-6] [PMID: 7538237]
[44]
Roessler W, Hinke A, Wieland WF. Experience in advanced prostatic cancer: Orchiectomy and flutamide versus orchiectomy and estramustine phosphate. Urology 1994; 43(2)(Suppl.): 57-60.
[http://dx.doi.org/10.1016/0090-4295(94)90220-8] [PMID: 8116134]
[45]
Tyrrell CJ, Altwein JE, Klippel F, et al. Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. Cancer 1993; 72(12)(Suppl.): 3878-9.
[http://dx.doi.org/10.1002/1097-0142(19931215)72:12+<3878:AID-CNCR2820721723>3.0.CO;2-L] [PMID: 8252508]
[46]
Janknegt RA. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Cancer 1993; 72: 3874-7.
[47]
McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2(1): 18-27.
[PMID: 10388026]
[48]
Keuppens F, Whelan P, Carneiro de Moura JL, et al. Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group. Cancer 1993; 72(12)(Suppl.): 3863-9.
[http://dx.doi.org/10.1002/1097-0142(19931215)72:12+<3863:AID-CNCR2820721720>3.0.CO;2-9] [PMID: 8252505]
[49]
Iversen P, Rasmussen F, Klarskov P, Christensen IJ. Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer 1993; 72(12)(Suppl.): 3851-4.
[http://dx.doi.org/10.1002/1097-0142(19931215)72:12] [PMID: 8252502]
[50]
Akaza H, Usami M, Kotake T, Koiso K, Aso Y. A randomized phase II trial of flutamide vs. chlormadinone acetate in previously untreated advanced prostatic cancer. Jpn J Clin Oncol 1993; 23(3): 178-85.
[PMID: 7688829]
[51]
Boccardo F, Pace M, Rubagotti A, et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer 1993; 29A(8): 1088-93.
[http://dx.doi.org/10.1016/S0959-8049(05)80293-X] [PMID: 8518017]
[52]
Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149(1): 77-82.
[http://dx.doi.org/10.1016/S0022-5347(17)36003-2] [PMID: 7678043]
[53]
Tyrrell CJ, Altwein JE, Klippel F, et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol 1991; 146(5): 1321-6.
[http://dx.doi.org/10.1016/S0022-5347(17)38080-1] [PMID: 1834864]
[54]
Beland G. Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study. Urology 1991; 37(2)(Suppl.): 25-9.
[http://dx.doi.org/10.1016/0090-4295(91)80098-R] [PMID: 1992600]
[55]
Namer M, Toubol J, Caty A, et al. A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer. J Steroid Biochem Mol Biol 1990; 37(6): 909-15.
[http://dx.doi.org/10.1016/0960-0760(90)90442-N] [PMID: 2285605]
[56]
Denis L, Robinson M, Mahler C, et al. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853). J Steroid Biochem Mol Biol 1990; 37(6): 951-9.
[http://dx.doi.org/10.1016/0960-0760(90)90449-U] [PMID: 2149508]
[57]
Crawford ED, Allen JA. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036. J Steroid Biochem Mol Biol 1990; 37(6): 961-3.
[http://dx.doi.org/10.1016/0960-0760(90)90450-Y] [PMID: 2126738]
[58]
Béland G, Elhilali M, Fradet Y, et al. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer 1990; 66(5)(Suppl.): 1074-9.
[http://dx.doi.org/10.1002/cncr.1990.66.s5.1074] [PMID: 2203517]
[59]
Iversen P, Christensen MG, Friis E, et al. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 1990; 66(5)(Suppl.): 1058-66.
[http://dx.doi.org/10.1002/cncr.1990.66.s5.1058] [PMID: 2144207]
[60]
Keuppens F, Denis L, Smith P, et al. Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. Cancer 1990; 66(5)(Suppl.): 1045-57.
[http://dx.doi.org/10.1002/cncr.1990.66.s5.1045] [PMID: 2144206]
[61]
Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990; 66(5)(Suppl.): 1039-44.
[http://dx.doi.org/10.1002/cncr.1990.66.s5.1039] [PMID: 2118417]
[62]
Kimura G, Yonese J, Fukagai T, et al. Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial. Int J Urol 2016; 23(5): 395-403.
[http://dx.doi.org/10.1111/iju.13072] [PMID: 27018069]
[63]
Siemens DR, Klotz L, Heidenreich A, et al. Efficacy and safety of enzalutamide vs. bicalutamide in younger and older patients with metastatic castration resistant prostate cancer in the TERRAIN Trial. J Urol 2018; 199(1): 147-54.
[http://dx.doi.org/10.1016/j.juro.2017.08.080] [PMID: 28827103]
[64]
Merseburger AS, Scher HI, Bellmunt J, et al. Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int 2015; 115(1): 41-9.
[http://dx.doi.org/10.1111/bju.12898] [PMID: 25123978]
[65]
Kim CS, Theeuwes A, Kwon DD, et al. The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients. Investig Clin Urol 2016; 57(3): 174-83.
[http://dx.doi.org/10.4111/icu.2016.57.3.174] [PMID: 27195316]
[66]
Denis LJ, Carnelro de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). Urology 1993; 42(2): 119-29.
[http://dx.doi.org/10.1016/0090-4295(93)90634-M] [PMID: 8367920]
[67]
Chung BH, Horie S, Chiong E. The incidence, mortality and risk factors of prostate cancer in Asian men. Prostate Int 2019; 7(1): 1-8.https://dx.doi.org/10.1016%2Fj.prnil.2018.11.001
[68]
Rashid M, Shamshavali K, Vsn M, et al. Efficacy and safety of enzalutamide in metastatic prostate cancer patients: A systematic review and meta-analysis. Value Health 2018; 21: S16.
[http://dx.doi.org/10.1016/j.jval.2018.04.092]
[69]
Luchini C, Fleischmann A, Boormans JL, et al. Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: A systematic review and meta-analysis. Sci Rep 2017; 7(1): 2374.
[http://dx.doi.org/10.1038/s41598-017-02577-4] [PMID: 28539662]
[70]
Kantoff PW, Taplin ME, Smith JA. Clinical presentation and diagnosis of prostate cancer 2018.
[71]
Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95(2): 361-76.
[http://dx.doi.org/10.1002/cncr.10647] [PMID: 12124837]
[72]
Bertagna C, De Géry A, Hucher M, François JP, Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 1994; 73(4): 396-402.
[http://dx.doi.org/10.1111/j.1464-410X.1994.tb07603.x] [PMID: 8199827]
[73]
Rashid M, Shamshavali K, Chhabra M. Efficacy and safety of Nilutamide in patients with metastatic prostate cancer who underwent orchiectomy: A systematic review and meta-analysis. Curr Clin Pharmacol 2019; 14(2): 108-15.
[http://dx.doi.org/10.2174/1574884714666190112151202] [PMID: 30648519]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Page: [34 - 47]
Pages: 14
DOI: 10.2174/1574887114666191105152404
Price: $65

Article Metrics

PDF: 22
HTML: 5
EPUB: 2
PRC: 2